RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx reported that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont testing intra-arterial gemcitabine delivered via the RenovoCath TAMP platform as neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma. The study will assess tumor regression, intraoperative surgical margins, and safety as UVM plans to enroll approximately 10 patients.